Claims
- 1. A neutralizing HEV polypeptide comprising at least about fifty amino acid residues between amino acid residues 452 and 617 from the C-terminal of the HEV pORF2 protein, including at least one neutralizing epitope.
- 2. A neutralizing HEV polypeptide comprising at least about 100 amino acid residues between amino acid residues 452 and 617 from the C-terminal of the HEV pORF2 protein, including at least one neutralizing epitope.
- 3. A neutralizing HEV polypeptide comprising amino acid residues 452 through 617 of the C-terminal of the HEV pORF2 protein.
- 4. A polypeptide that models the neutralizing epitope of HEV comprising amino acid residues 452 to 617 from the C-terminal of the HEV pORF2 protein.
- 5. A nucleotide that encodes the polypeptide of claim 1, 2, 3, or 4.
- 6. A pharmaceutical composition comprising the polypeptide of claim 1, 2, 3, or 4 or the nucleotide of claim 5.
- 7. An antibody elicited to the polypeptide of claim 1, 2, 3, or 4.
Government Interests
[0001] This invention was made at the Centers for Disease Control and Prevention. Therefore, the United States Government has certain rights in this invention.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/10696 |
4/3/2001 |
WO |
|